Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 22, 2017
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has six approved drugs.| International Patents: | 229 |
| US Patents: | 18 |
| Tradenames: | 7 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Drug Master File Entries: (click here to view) | 37 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
prasugrel hydrochloride | Tablets | 5 mg and 10 mg | EFFIENT | 7/10/2013 |
testosterone | Topical Solution | 30 mg/1.5 mL | AXIRON | 1/29/2013 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,427,275 | Medication dispensing apparatus with triple screw threads for mechanical advantage | ► Subscribe | |||||||||||||
| 6,929,801 | Transdermal delivery of antiparkinson agents | ► Subscribe | |||||||||||||
| 5,436,242 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation | ► Subscribe | |||||||||||||
| 8,357,393 | Transdermal delivery rate control using amorphous pharmaceutical compositions | ► Subscribe | |||||||||||||
| 7,094,422 | Topical delivery of antifungal agents | ► Subscribe | |||||||||||||
| 7,387,789 | Transdermal delivery of non-steroidal anti-inflammatory drugs | ► Subscribe | |||||||||||||
| 6,916,486 | Transdermal delivery of analgesics | ► Subscribe | |||||||||||||
| 8,177,449 | Spreading implement | ► Subscribe | |||||||||||||
| 6,916,487 | Transdermal delivery of antiemetics | ► Subscribe | |||||||||||||
| 6,964,777 | Transdermal delivery of antianxiety agents | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Japan | H0641139 | ► Subscribe | |||||||||||||
| European Patent Office | 1674068 | ► Subscribe | |||||||||||||
| Eurasian Patent Organization | 015473 | ► Subscribe | |||||||||||||
| New Zealand | 507980 | ► Subscribe | |||||||||||||
| Japan | 5114496 | ► Subscribe | |||||||||||||
| Israel | 103098 | ► Subscribe | |||||||||||||
| South Korea | 20050045946 | ► Subscribe | |||||||||||||
| Portugal | 884053 | ► Subscribe | |||||||||||||
| New Zealand | 578883 | ► Subscribe | |||||||||||||
| Hungary | 0400644 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2005 | Austria | ► Subscribe | PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005 | ||||||||||||
| 00397 | Netherlands | ► Subscribe | PRODUCT NAME: PRASUGREL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/08/503/001-014 20090225 | ||||||||||||
| 973 | Luxembourg | ► Subscribe | 91973, EXPIRES: 20220219 | ||||||||||||
| 00698 | Netherlands | ► Subscribe | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 | ||||||||||||
| 226 | Luxembourg | ► Subscribe | PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121 | ||||||||||||
| 13/34 | Ireland | ► Subscribe | PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013 | ||||||||||||
| C/GB05/024 | United Kingdom | ► Subscribe | PRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929 | ||||||||||||
| 91022-0 | Sweden | ► Subscribe | PRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN | ||||||||||||
| C/GB04/036 | United Kingdom | ► Subscribe | PRODUCT NAME: INSULIN DETEMIR, NEB29- TETRADECANOYL- DES(B30) HUMAN INSULIN; NATL REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: CH 56370, 56311, 56372 20031110 | ||||||||||||
| 2013000062 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,983 others who get our Drug Patent Expiration Alerts:
